Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Uveal Melanoma, Version 1.2019 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Rao, P., Barker, C., Coit, D. G., Joseph, R. W., Materin, M., Rengan, R., Sosman, J., Thompson, J. A., Albertini, M. R., Boland, G., Carson, W. E., Contreras, C., Daniels, G. A., DiMaio, D., Durham, A., Fields, R. C., Fleming, M. D., Galan, A., Gastman, B., Grossman, K., Guild, V., Johnson, D., Karakousis, G., Lange, J. R., Margolin, K., Nath, S., Olszanski, A. J., Ott, P. A., Ross, M. I., Salama, A. K., Skitzki, J., Swetter, S. M., Wuthrick, E., McMillian, N. R., Engh, A. 2020; 18 (2): 121–31

Abstract

The NCCN Guidelines for Uveal Melanoma include recommendations for staging, treatment, and follow-up of patients diagnosed with uveal melanoma of the choroid or ciliary body. In addition, because distinguishing between uveal melanoma and benign uveal nevi is in some cases difficult, these guidelines also contain recommendations for workup of patients with suspicious pigmented uveal lesions, to clarify the tests needed to distinguish between those who should have further workup and treatment for uveal melanoma versus those with uncertain diagnosis and low risk who should to be followed and later reevaluated. These NCCN Guidelines Insights describe recommendations for treatment of newly diagnosed nonmetastatic uveal melanoma in patients who have already undergone a complete workup.

View details for DOI 10.6004/jnccn.2020.0007

View details for Web of Science ID 000512898500003

View details for PubMedID 32023525